Academia and Industry: Us vs Them
Is ensuring integrity within the clinical trials enterprise, as some claim, beyond the reach of industry?
In his July Clinical Trials Insight column, Kenneth Getz examines the recent harsh criticisms by academia aimed at industry research. Although for years academia has considered itself above industry, as of late some academics are taking their bias to the extreme, “calling for industry to have no involvement in clinical research,” according to Getz. They believe that the problems within the enterprise, such as conflicts of interest or unethical practices, are isolated to industry and suggest that only academic-based professionals can ensure integrity.
Check out how Getz responds to this view in “Are Academia and NIH Bastions of Integrity” and then let us know how you feel about it in an email to actspecialprojects@advanstar.com.
Responses and discussion regarding this topic will appear in a future blog post on this Web site.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
